CHAPTER

Biomedical and Therapeutic Applications of Biosurfactants

Lígia R. Rodrigues* and José A. Teixeira

Abstract

During the last years, several applications of biosurfactants with medical purposes have been reported. Biosurfactants are considered relevant molecules for applications in combating many diseases and as therapeutic agents due to their antibacterial, antifungal and antiviral activities. Furthermore, their role as anti-adhesive agents against several pathogens illustrate their utility as suitable anti-adhesive coating agents for medical insertional materials leading to a reduction of a large number of hospital infections without the use of synthetic drugs and chemicals. Biomedical and therapeutic perspectives of biosurfactants applications are presented and discussed in this review.

Introduction

Biosurfactants are microbial compounds that exhibit pronounced surface and emulsifying activities. These compounds comprise a wide range of chemical structures, such as glycolipids, lipopeptides, polysaccharide-protein complexes, phospholipids, fatty acids and neutral lipids.¹⁻⁷ Therefore, it is reasonable to expect diverse properties and physiological functions for different groups of biosurfactants. Comparing with chemical surfactants, these compounds have several advantages such as lower toxicity, higher biodegradability and effectiveness at extreme temperatures or pH values.⁶⁻¹⁰ Although these compounds present interesting features as compared with their chemical counterparts, many of the envisaged applications depend considerably on whether they can be produced economically. Hence, much effort in process optimization and at the engineering and biological levels has been carried out. Biosurfactants production from inexpensive waste substrates and low cost raw materials, thereby decreasing their production cost,¹¹⁻¹⁸ has been reported. Furthermore, these molecules can be tailor-made to suit different applications by changing the growth substrate or growth conditions.¹⁹⁻²⁰ Most biosurfactants are considered secondary metabolites, though, some may play essential roles for the survival of the producing-microorganisms either through facilitating nutrient transport, microbe-host interactions or as biocide agents.⁶ Biosurfactant roles include increasing the surface area and bioavailability of hydrophobic water-insoluble substrates, heavy metal binding, bacterial pathogenesis, quorum sensing and biofilm formation.²¹ An interface is any boundary between two different phases and microbial life may be more common at interfaces as evidenced by microbial biofilms, surface films and aggregates. Given that, all microbial life is impacted by interfacial phenomena and biosurfactants are a common mechanism by which microorganisms deal with interfacial challenges.⁶ Biosurfactants are amphipatic molecules with both hydrophilic and hydrophobic moieties that partition preferentially at the interface between fluid phases that have different degrees of polarity and hydrogen bond-

*Corresponding Author: Lígia R Rodrigues—IBB, Centre of Biological Engineering, Universidade do Minho, Campus de Gualtar, 4710-057 Braga, Portugal.
Email: lrmr@deb.uminho.pt

ing, such as oil and water, or air and water interfaces. In addition to this behaviour, their diversity, environmentally friendly nature, suitability for large-scale production and selectivity, has driven most of the research in biosurfactants field for environmental applications.^{7,22-25} Legal aspects such as stricter regulations concerning environmental pollution by industrial activities and health regulations will also strongly influence the chances of biodegradable biosurfactants replacing their chemical counterparts.^{7,10,19,22-25}

Regardless of the potential and biological origin of biosurfactants few studies were carried out on applications related to biomedical applications.^{11,26-30} Nevertheless, some biosurfactants have proven to be suitable alternatives to synthetic medicines and antimicrobial agents and may therefore be used as safe and effective therapeutic agents (Table 1).

The biosurfactants potential applications in the medical field, as well as their main mechanisms of interaction are discussed in this review.

Biomedical and Therapeutic Applications of Biosurfactants

As discussed above a broad range of chemical structures have been attributed to biosurfactants.^{1-2,4-5} Some of these biosurfactants were described for their potential as biological active compounds and applicability in the medical field. Therefore, they are a suitable alternative to synthetic medicines and antimicrobial agents and may be used as safe and effective therapeutic agents.^{21,25} Recently, there has been an increasing interest in the effect of biosurfactants on human and animal cells and cell lines.^{28,42,83} Lipopeptides produced by *Bacillus subtilis*³⁶ and *Bacillus licheniformis*,^{19,49-51} mannosylerythritol lipids produced by *Candida antarctica*⁵³ and rhamnolipids produced by *Pseudomonas aeruginosa*,³³⁻³⁴ have been shown to have antimicrobial activities.

Biological Activity

Glycolipids

Glycolipids are the most common group of biosurfactants of which the most effective regarding surface active properties are the trehalose lipids obtained from *Mycobacterium* and related bacteria, the rhamnolipids obtained from *Pseudomonas* sp. and the sophorolipids obtained from yeasts. Otto and coworkers¹² described the production of sophorose lipids using deproteinized whey concentrate as substrate by a two-stage process. Several antimicrobial, immunological and neurological properties have been attributed to mannosylerythritol lipid (MEL), a yeast glycolipid biosurfactant, produced from vegetable oils by *Candida* strains.^{62,84} Kitamoto et al⁵³ showed that MEL exhibits antimicrobial activity particularly against gram-positive bacteria. Isoda et al⁵⁴ investigated the biological activities of seven extracellular microbial glycolipids including MEL-A, MEL-B, polyol lipid, rhamnolipid, sophorose lipid and succinoyl trehalose lipid STL-1 and STL-3. Except for rhamnolipid, all the other tested glycolipids induced cell differentiation instead of cell proliferation in the human promyelocytic leukaemia cell line HL60. These glycolipids induced the human myelogenous leukaemia cell line K562 and the human basophilic leukaemia cell line Ku812 to differentiate into monocytes, granulocytes and megakaryocytes. STL and MEL differentiation-inducing activity was attributed to a specific interaction with the plasma membrane instead of a simple detergent-like effect.

In addition, the effects of several kinds of microbial extracellular glycolipids on neurite initiation in PC12 cells were investigated.⁵⁵ The PC12 cell line derived from a rat pheochromocytoma, provides a relatively simple and homogeneous system for studying various aspects of neuronal differentiation, because PC12 cells can survive and proliferate without requiring the presence of neurotrophic factors. A significant neurite outgrowth was observed as a consequence of the addition of MEL-A, MEL-B and sophorose lipid (SL) to PC12 cells. MEL-A increased acetylcholinesterase activity to an extent similar to nerve growth factor (NGF). MEL-A induced neurite outgrowth after treatment of PC12 cells with an anti-NGF receptor antibody that obstructed the NGF action. It was shown that MEL-A and NGF induce differentiation of PC12 cells through different mechanisms. Moreover, MEL was found to induce the outgrowth of neurites, enhance

Table 1. Examples of biosurfactants application in the medical field (adapted from Rodrigues et al²⁸)

Microorganism	Biosurfactant Type	Activity/Application	Reference
<i>Pseudomonas aeruginosa</i>	Rhamnolipid	• Antimicrobial activity against <i>Mycobacterium tuberculosis</i>	31-35
		• Anti-adhesive activity against several bacterial and yeast strains isolated from voice prostheses	
		• Induced dose-dependent hemolysis and coagulation of platelet-poor plasma but is not detrimental to chicken lung, liver, heart and kidney tissues	
<i>Bacillus subtilis</i>	Surfactin	• Antimicrobial and antifungal activities	36-43
		• Inhibition of fibrin clot formation	
		• Hemolysis and formation of ion channels in lipid membranes	
<i>Bacillus subtilis</i>	Pumilacidin (surfactin analog)	• Antitumor activity against Ehrlich's ascite carcinoma cells	44
		• Antiviral activity against human immunodeficiency virus 1 (HIV-1)	
		• Induction of apoptosis in human leukemia K562	
<i>Bacillus subtilis</i>	Iturin	• Antiviral activity against herpes simplex virus 1 (HSV-1)	5,45-48
		• Inhibitory activity against H ⁺ , K ⁺ -ATPase and protection against gastric ulcers in vivo	
		• Antimicrobial activity and antifungal activity against profound mycosis	
<i>Bacillus subtilis</i>		• Effect on the morphology and membrane structure of yeast cells	
		• Increase in the electrical conductance of biomolecular lipid membranes	

continued on next page

Table 1. Continued

Microorganism	Biosurfactant Type	Activity/Application	Reference
<i>Bacillus licheniformis</i>	Lichenysin	<ul style="list-style-type: none"> • Nontoxic and nonpyrogenic immunological adjuvant • Antibacterial activity 	49-52
<i>Candida antarctica</i>	Mannosylerythritol lipids	<ul style="list-style-type: none"> • Chelating properties that might explain the membrane disrupting effect of lipopeptides • Antimicrobial, immunological and neurological properties 	53-66
<i>Rodococcus erythropolis</i>	Trehalose lipid	<ul style="list-style-type: none"> • Induction of cell differentiation in the human promyelocytic leukemia cell line HL60 • Induction of neuronal differentiation in PC12 cells • Enhancement of gene transfection efficiency 	67-68
<i>Streptococcus thermophilus</i>	Glycolipid	<ul style="list-style-type: none"> • Antiviral activity against HSV and influenza virus • Anti-adhesive activity against several bacterial and yeast strains isolated from voice prostheses 	69-73
<i>Streptococcus mitis</i>	Not identified	<ul style="list-style-type: none"> • Anti-adhesive activity against <i>Streptococcus mutans</i> 	74-75
<i>Lactobacillus</i>	Surlactin	<ul style="list-style-type: none"> • Anti-adhesive activity against several pathogens including enteric bacteria 	76-81
<i>Lactococcus lactis</i>	Not identified	<ul style="list-style-type: none"> • Anti-adhesive activity against several bacterial and yeast strains isolated from voice prostheses 	70, 82

the activity of acetylcholinesterase and increase the levels of galactosylceramide from PC12 pheochromocytoma cells.⁵⁶

Glycolipids have also been implicated with growth arrest, apoptosis and the differentiation of mouse malignant melanoma cells.⁵⁷⁻⁵⁸ Exposure of B16 cells to MEL resulted in the condensation of the chromatin, DNA fragmentation and sub-G1 arrest (the sequence of events of apoptosis). Furthermore, MEL was reported to markedly inhibit the growth of mouse melanoma B16 cells in a dose-dependent manner. Moreover, MEL exposure stimulated the expression of differentiation markers of melanoma cells, such as tyrosinase activity and the enhanced production of melanin, which is an indication that MEL triggered both apoptotic and cell differentiation programs. In addition, exposure of PC12 cells to MEL enhanced the activity of acetylcholinesterase and interrupted the cell cycle at the G1 phase, with resulting outgrowth of neurites and partial cellular differentiation.⁵⁹ MEL has been implicated in the induction of neuronal differentiation in PC12 cells and therefore provides the basis for the use of glycolipids as therapeutical agents for cancer treatment. Nevertheless, further studies of the molecular basis of the signalling cascade that follows exposure of PC12 cells to MEL may ultimately lead to a better understanding of the processes that result in the outgrowth of neurites and the commitment to differentiation of PC12 cells.

In other studies, four analogs of STL-3 at their critical micelle concentration were evaluated for their ability to inhibit growth and induce differentiation of HL60 human promyelocytic leukaemia cells.⁸⁵ It was found that the effect of STL-3 and its analogs on HL60 cells was dependent on the hydrophobic moiety of STL-3. Furthermore, a high binding-affinity of MEL towards human immunoglobulin G (HlgG) was shown by Im et al.⁸⁶ They suggested the possibility of using MEL-A as an alternative ligand for immunoglobulins. In subsequent studies they evaluated the potential of MEL (-A, -B and -C) attached to PHEMA beads (poly(2-hydroxyethyl methacrylate)), for binding, affinity to HlgG.⁸⁷ Of these three composite compounds, those bearing MEL-A exhibited the highest binding capacity to HlgG. More significantly, the bound HlgG was efficiently recovered (approximately 90%) under significantly mild elution conditions, with phosphate buffer at pH 7, indicating a great potential of the glycolipids as an affinity ligand material. Other researchers also demonstrated that MEL-A assembled monolayers would be useful as noble affinity ligand system for various immunoglobulins.⁶⁴⁻⁶⁵ Inoh et al.⁸⁸⁻⁸⁹ reported that MEL-A significantly increased the efficiency of gene transfection mediated by cationic liposomes with a cationic cholesterol derivative. Among the cationic liposomes tested, the liposome bearing cholesteryl-3 β -carboxyaminoethylamine and MEL-A showed the best efficiency for delivery of plasmids encoding luciferase (pGL3) into the target cells (NIH3T3, COS-7 and HeLa). The properties, production and applications of MEL were widely studied by Kitamoto and coworkers⁹⁰ and by Ueno et al.,⁶⁰⁻⁶¹ particularly the exceptional interfacial properties and differentiation-inducing activities of MEL. They also focused on the excellent biological and self-assembling actions of MEL and examined the effect of MEL-A on the gene transfection using cationic liposomes. These results were also demonstrated by other researchers that studied the transfection efficiency in human cervix carcinoma Hela cells⁶⁶ and the potential of these liposomes as vectors for herpes simplex virus thymidine kinase gene therapy.⁶³

The succinoyl-trehalose lipid produced by *Rhodococcus erythropolis* has also been reported to inhibit HSV and influenza virus.⁶⁷⁻⁶⁸ The deficiency of pulmonary surfactant which is responsible for respiration failure in premature infants⁹¹ may be corrected through the isolation of genes for protein molecules of this surfactant and cloning in bacteria for possible fermentative production and use in medical application.³³ Sano et al.⁹² demonstrated the different actions of pulmonary surfactant protein A upon distinct serotypes of LPS which is the major constituent of the outer membrane of gram-negative bacteria.

Lipopeptides

Several features and biological activities have been reported for lipopeptides, mainly for iturin A and surfactin. They have been described as antibiotics, antiviral and antitumor agents, immunomodulators or specific toxins and enzyme inhibitors. Ahimou et al.⁵ reported that lipopeptide

profile and bacterial hydrophobicity vary greatly with the producing strains, iturin A being the only lipopeptide type produced by all *B. subtilis* strains. Surfactin was found to be more efficient than iturin A in modifying the *B. subtilis* surface hydrophobic character. Morikawa et al.¹ identified and characterized a biosurfactant, arthrofatin, produced by *Arthrobacter* species, which was found to be seven times more effective than surfactin. Jenny and coworkers⁴⁹ determined the structural analysis and characterized surface activities of biosurfactants produced by *B. licheniformis*, while several researchers described their continuous production.^{50,93} Yakimov and coworkers⁵¹ demonstrated the antibacterial activity of lichenysin A, a biosurfactant produced by *B. licheniformis* that favourably compares to others surfactants. More recently Grangemard et al.⁵² reported the chelating properties of lichenysin, which might explain the membrane disrupting effect of lipopeptides.

In another study, Carrillo and its collaborators⁹⁴ proposed a molecular mechanism of membrane permeabilization by surfactin, which may explain surfactin induced pore formation underlying the antibiotic and haemolytic action of these lipopeptides. This study also suggested that the membrane barrier properties are likely to be damaged in the areas where surfactin oligomers interact with the phospholipids, at concentrations much below the onset for solubilisation. Such properties can cause structural fluctuations that may well be the primary mode of the antibiotic action of this lipopeptide. Surfactin type peptides that can rapidly act on membrane integrity rather than other vital cellular processes may perhaps constitute the next generation of antibiotics. Lipopeptide surfactin has been found to interact with artificial and biomembrane systems, for example bacterial protoplasts or enveloped viruses.³⁶ Several biological activities have been attributed to surfactin including the induction of ion channels formation in lipid bilayer membranes,⁴⁰ the inhibition of fibrin clot formation and haemolysis,³⁹ the inhibition of cyclic adenosine monophosphate (cAMP), the inhibition of platelet and spleen cytosolic phospholipase A2 (PLA2)⁹⁵ and antimicrobial, antiviral and antitumor activity against Ehrlich's ascite carcinoma cells.^{38,95} According to the differences in their amino acid sequences, different types of surfactins (A, B and C) have been identified. Surfactin C was found to enhance the activation of prourokinase (plasminogen activator) and the conformational change in plasminogen, leading to increased fibrinolysis in vitro and in vivo.⁹⁶ The plasminogen-plasmin system is involved in blood clot dissolution, as well as in a variety of physiological and pathological processes requiring localized proteolysis. In a rat pulmonary embolism model, surfactin C increases plasma clot lyses when injected in combination with prourokinase.⁸³ The results gathered in this study point to the possible use of surfactin in thrombolytic therapy related to pulmonary, myocardial and cerebral disorders.

Vollenbroich and coworkers³⁶ showed that a surfactin treatment improved proliferation rates and lead to changes in the morphology of mammalian cells that had been contaminated with mycoplasma. Furthermore, the low cytotoxicity of surfactin to mammalian cells allowed specific inactivation of mycoplasmas without significant damaging effects on cell metabolism.^{42,43} Additionally, surfactin and surfactin analogs have been reported as antiviral agents, namely it was demonstrated a significant inhibitory effect of pumilacidin on herpes simplex virus 1 (HSV-1)⁴⁴ and an inhibitory activity against H⁺, K⁺-ATPase and protection against gastric ulcers in vivo. The potential of surfactin against human immunodeficiency virus 1 (HIV-1) was reported by Itokawa et al.⁴¹ The antiviral action of surfactin was suggested to be due to physicochemical interactions between the membrane-active surfactant and the virus lipid membrane, which causes permeability changes and at higher concentrations leads finally to the disintegration of the mycoplasma membrane system by a detergent effect.³⁷ Furthermore, surfactin was found to be active against Semliki Forest virus, herpes simplex virus, suid herpes virus, vesicular stomatitis virus, simian immunodeficiency virus, feline calicivirus and murine encephalomyocarditis virus.³⁷

Moreover, Kim and coworkers⁹⁵ demonstrated that surfactin is a selective inhibitor for cytosolic PLA2 and a putative anti-inflammatory agent through the inhibitory effect produced by direct interaction with cytosolic PLA2 and that inhibition of cytosolic PLA2 activity may suppress inflammatory responses.

Another lipopeptide, iturin A, produced by *B. subtilis* was reported to have effective antifungal properties^{5,46} which affects the morphology and membrane structure of yeast cells. This lipopeptide

was shown to pass through the cell wall and disrupt the plasma membrane with the formation of small vesicles and the aggregation of intramembranous particles. Iturin also passes through the plasma membrane and interacts with the nuclear membrane and probably with membranes of other cytoplasmic organelles. This lipopeptide has been proposed as an effective antifungal agent for profound mycosis.⁴⁷ Other members of the iturin group, including bacillomycin D and bacillomycin Lc were also found to have antimicrobial activity against *Aspergillus flavus*, but the different lipid chain length apparently affected the activity of the lipopeptide against other fungi.⁹⁷ Thus, the members of the iturin-like biosurfactant group are considered alternative antifungal agents.

Possible applications of biosurfactants as emulsifying aids for drug transport to the infection site, for supplementing pulmonary surfactant and as adjuvants for vaccines were suggested by Kosaric.⁹⁸ Mittenbuhler et al⁴⁸ showed that bacterial lipopeptides constitute powerful nontoxic and nonpyrogenic immunological adjuvants when mixed with conventional antigens. A marked enhancement of the humoral immune response was obtained with the low molecular mass antigens iturin AL, herbicolin A and microcystin (MLR) coupled to poly-L-lysine (MLR-PLL) in rabbits and in chickens. Conjugates of lipopeptide—Th-cell epitopes also constituted effective adjuvants for the in vitro immunization of either human mononuclear cells or mouse B cells with MLR-PLL and result in a significantly increased yield of antibody-secreting hybridomas.

Other Biosurfactants

Nielsen and coworkers⁹⁹ reported viscosinamide, a cyclic depsipeptide, as a new antifungal surface active agent produced by *Pseudomonas fluorescens* and with different properties as compared to the biosurfactant viscosin, known to be produced from the same species and to have antibiotic activity.¹⁰⁰ Massetolides A-H, also cyclic depsipeptides, were isolated from *Pseudomonas* species, derived from a marine habitat and found to exhibit in vitro antimicrobial activity against *Mycobacterium tuberculosis* and *Mycobacterium avium-intracellulare*.³¹

Precursors and degeneration products of sphingolipids biosurfactants were found to inhibit the interaction of *Streptococcus mitis* with buccal epithelial cells and of *Staphylococcus aureus* with nasal mucosal cells.¹⁰¹ Gram-positive *Bacillus pumilis* cells were found to produce pumilacidin A, B, C, D, E, F and G which exhibited antiviral activity against herpes simplex virus 1 (HSV-1), inhibitory activity against H⁺, K⁺-ATPase and were found to be protective against gastric ulcers⁴⁴ probably through inhibiting microbial activity contributing to these ulcers.

Although there is an increasing potential for the application of biosurfactants in the biomedical field, some of these molecules may constitute a risk for humans. For instance, *P. aeruginosa* is a bacterium responsible for severe nosocomial infections, life-threatening infections in immunocompromised persons and chronic infections in cystic fibrosis patients; thus rhamnolipids have to be well investigated prior to such uses. *P. aeruginosa* strain's virulence depends on a large number of cell-associated and extracellular factors.¹⁰²⁻¹⁰⁴ Cell-to-cell signalling systems control the expression and allow a coordinated, cell-density-dependent production of many extracellular virulence factors. The possible role of cell-to-cell signalling in the pathogenesis of *P. aeruginosa* infections and a rationale for targeting cell-to-cell signalling systems in the development of new therapeutic approaches was discussed by Van Delden and Igilewski.¹⁰² Synthesis of rhamnolipids is regulated by a very complex genetic regulatory system that also controls different *P. aeruginosa* virulence-associated traits.³⁴ The possible application of rhamnolipids in the pharmaceutical industry is still being studied by some researchers.^{35,105} The cosmetic and health care industries use large amounts of surfactants for a wide variety of products including insect repellents, antacids, acne pads, contact lens solutions, hair colour and care products, deodorants, nail care products, lipstick, eye shadow, mascara, toothpaste, denture cleaners, lubricated condoms, baby products, foot care products, antiseptics, shaving and depilatory products.⁸ Biosurfactants are known to have advantages over synthetic surfactants such as low irritancy or anti-irritating effects and compatibility with skin. Rhamnolipids in particular are being used as cosmetic additives and have been patented to make some liposomes and emulsions,¹⁰³⁻¹⁰⁴ both of which are important in the cosmetic industry.

Anti-Adhesive Activity

Biosurfactants have been found to inhibit the adhesion of pathogenic organisms to solid surfaces or to infection sites, thus prior adhesion of biosurfactants to solid surfaces of implant materials might constitute a new and effective means of combating colonization by pathogenic microorganisms.²¹ Precoating vinyl urethral catheters by running the surfactin solution through them before inoculation with media resulted in a decrease of the amount of biofilm formed by *Salmonella typhimurium*, *Salmonella enterica*, *Escherichia coli* and *Proteus mirabilis*.¹⁰⁶ Given the importance of opportunistic infections with *Salmonella* species, including urinary tract infections of AIDS patients, these results have great potential for practical applications.

A role for biosurfactants as defence weapons in post adhesion competition with other strains or species has to date been suggested only for biosurfactants released by *S. mitis* strains against *Streptococcus mutans* adhesion⁷⁴⁻⁷⁵ and for biosurfactants released by lactobacilli against adhesion of uropathogens.⁷⁷⁻⁷⁸ The biosurfactant surfactin,⁷⁹ produced by several *Lactobacillus* isolates, was suggested as a suitable anti-adhesive coating for catheter materials. The role of *Lactobacillus* species in the female urogenital tract as a barrier to infection is of considerable interest.¹⁰⁷ These organisms are believed to contribute to the control of vaginal microbiota by competing with other microorganisms for adherence to epithelial cells and by producing biosurfactants. There are reports of inhibition of biofilm formation by uropathogens and yeast on silicone rubber with biosurfactants produced by *Lactobacillus acidophilus*.¹⁰⁸⁻¹⁰⁹ Heinemann and coworkers showed that *Lactobacillus fermentum* RC-14 releases surface-active components that can inhibit adhesion of uropathogenic bacteria, including *Enterococcus faecalis*.¹¹⁰ Velraeds et al⁸⁰ also reported on the inhibition of adhesion of pathogenic enteric bacteria by a biosurfactant produced by a *Lactobacillus* strain and later showed that the biosurfactant caused an important, dose-related inhibition of the initial deposition rate of *E. coli* and other bacteria adherent on both hydrophobic and hydrophilic substrata.⁷⁶

Dairy *S. thermophilus* strains were found to be biosurfactant-producers and Busscher et al⁷²⁻⁷³ showed that this biosurfactant inhibited adhesion onto silicone rubber and growth of several bacterial and yeast strains isolated from explanted voice prostheses. Efforts in the development of strategies to prevent the microbial colonization of silicone rubber voice prostheses have been reported by Rodrigues et al.^{71,82} The ability of biosurfactants obtained from the probiotic strains, *L. lactis* 53 and *S. thermophilus* A, to inhibit adhesion of four bacterial and two yeast strains isolated from explanted voice prostheses to precoated silicone rubber was evaluated. The results obtained showed that the biosurfactants were effective in decreasing the initial deposition rates, as well as the number of bacterial cells adhering after 4 h, for all microorganisms tested. Over 90% reductions in the initial deposition rates were achieved for most of the bacterial strains tested. Recently, the authors also demonstrated that a rhamnolipid biosurfactant containing solution may be useful for use as a biode detergent solution for prostheses cleaning, prolonging their lifetime and directly benefiting laryngectomized patients. Gotek et al⁸¹ assessed the adhesive properties of several biosurfactant-producers *Lactobacillus* spp. strains to a monolayer of intestinal epithelium in vitro, represented by the Caco2 cell line. All tested *Lactobacillus* strains showed adhesion to Caco2 cells. A 50% reduction in the population of *Klebsiella pneumoniae* 2 cells adhering to the surface previously impregnated with a solution of biosurfactants synthesised by *Lactobacillus casei* rhamnosus CCM 1825, after the 3-hour contact with the tested surface was also observed.

The role for surfactants in the defence against infection and inflammation in the human body is a well-known phenomenon. The pulmonary surfactant is a lipoprotein complex synthesized and secreted by the epithelial lung cells into the extracellular space, where it lowers the surface tension at the air-liquid interface of the lung and represents a key factor against infections and inflammatory lung diseases.⁹¹

Antimicrobial Activity

The antimicrobial activity of several biosurfactants has been reported in the literature for many different applications.¹¹¹ For instance, the antimicrobial activity of two biosurfactants obtained from probiotic bacteria, *L. lactis* 53 and *S. thermophilus* A, against a variety of bacterial and yeast

strains isolated from explanted voice prostheses was evaluated.⁷⁰ In another study, Reid et al¹¹²⁻¹¹³ emphasized a possible probiotic role for the biosurfactant-producing lactobacilli in the restoration and maintenance of healthy urogenital and intestinal tracts, conferring protection against pathogens and suggested a reliable alternative treatment and preventive regimen to antibiotics in the future. The first clinical evidence that probiotic lactobacilli can be delivered to the vagina following oral intake was provided¹¹³ and although only a limited set of strains have any proven clinical effect or scientific basis, there are sufficient data to suggest that this approach could provide a valuable alternative to antibiotic prophylaxis and treatment of infection. By the use of a rat model of surgical implant infection, Gan et al¹¹⁴ determined that the probiotic strain, *L. fermentum* RC-14 and its secreted biosurfactant reduced infections associated with surgical implants, which are mainly caused by *S. aureus* through inhibition of growth and reduction of adherence to surgical implants. A recent in vitro study of *Lactobacillus plantarum* 299v and *L. rhamnosus* GG showed that these probiotic strains could inhibit the adhesion of *E. coli* to intestinal epithelial cells by stimulating epithelial expression of mucins.¹¹⁵ These strains however were also found to be biosurfactant producers.¹⁴ These observations generally indicated that biosurfactants might also contain signalling factors that interact with host and/or bacterial cells leading to the inhibition of infections. Moreover they support the assertion of possible role in preventing microbial adhesion^{76,116} and their potential in developing anti-adhesion biological coatings for implant materials.³²

Conclusions

Interest in the use of biosurfactants in the medical field has been increasing in the last years as a result of many studies published on their unique features. Biosurfactants are not only useful as antibacterial, antifungal and antiviral agents, but also have potential for use as major immunomodulatory molecules, adhesive agents and even in vaccines and gene therapy. They have been used for gene transfection, as ligands for binding immunoglobulins, as adjuvants for antigens and also as inhibitors for fibrin clot formation and activators of fibrin clot lyses. Promising alternatives to produce potent biosurfactants with altered antimicrobial profiles and decreased toxicity against mammalian cells may be exploited by genetic alteration of biosurfactants. Furthermore, biosurfactants have the potential to be used as anti-adhesive biological coatings for biomaterials, thus reducing hospital infections and use of synthetic drugs and chemicals. They may also be incorporated into probiotic preparations to combat urogenital tract infections and pulmonary immunotherapy.

Regardless of the enormous potential of biosurfactants in this field, their use still remains limited, possibly due to their high production and extraction cost and lack of information on their toxicity towards human systems. Further research on human cells and natural microbiota are required to validate the use of biosurfactants in several biomedical and health related areas. Nevertheless, there appears to be great potential for their use in the medical science arena waiting to be fully exploited.

References

1. Morikawa M, Daido H, Takao T et al. A new lipopeptide biosurfactant produced by *Arthrobacter* sp. strain MIS38. *Journal of Bacteriology* 1993; 175:6459-6466.
2. Lin S. Biosurfactants: recent advances. *Journal of Chemical Technology and Biotechnology* 1996; 66:109-120.
3. Desai JD, Banat IM. Microbial production of surfactants and their commercial potential. *Microbiology and Molecular Biology Reviews* 1997; 61:47-64.
4. Angelova B, Schmauder H-P. Lipophilic compounds in biotechnology—interactions with cells and technological problems. *Journal of Biotechnology* 1999; 67:13-32.
5. Ahimou F, Jacques P, Deleu M. Surfactin and iturin A effects on *Bacillus subtilis* surface hydrophobicity. *Enzyme and Microbial Technology* 2001; 27:749-754.
6. Van Hamme JD, Singh A, Ward OP. Physiological aspects. Part 1 in a series of papers devoted to surfactants in microbiology and biotechnology. *Biotechnology Advances* 2006; 24:604-620.
7. Singh A, Van Hamme JD, Ward OP. Surfactants in microbiology and biotechnology: Part 2. Application aspects. *Biotechnology Advances* 2007; 25:99-121.

8. Kosaric N. Biosurfactants in industry. *Journal of the American Oil Chemists' Society* 1992; 64:1731-1737.
9. Cameotra S, Makkar R. Synthesis of biosurfactants in extreme conditions. *Applied Microbiology and Biotechnology* 1998; 50:520-529.
10. Mukherjee S, Das P, Sen R. Towards commercial production of microbial surfactants. *Trends in Biotechnology* 2006; 24:509-515.
11. Makkar R, Cameotra S. An update on the use of unconventional substrates for biosurfactant production and their new applications. *Applied Microbiology and Biotechnology* 2002; 58:428-434.
12. Otto RT, Daniel H-J, Pekin G et al. Production of sophorolipids from whey II.—Product composition, surface active properties, cytotoxicity and stability against hydrolases by enzymatic treatment. *Applied Microbiology and Biotechnology* 1999; 52:495-501.
13. Rodrigues LR, Teixeira JA, Oliveira R. Low cost fermentative medium for biosurfactant production by probiotic bacteria. *Biochemical Engineering Journal* 2006; 32:135-142.
14. Rodrigues LR, Moldes A, Teixeira JA et al. Kinetic study of fermentative biosurfactant production by lactobacillus strains. *Biochemical Engineering Journal* 2006; 28:109-116.
15. Das K, Mukherjee AK. Comparison of lipopeptide biosurfactants production by *Bacillus subtilis* strains in submerged and solid state fermentation systems using a cheap carbon source: some industrial applications of biosurfactants. *Process Biochemistry* 2007; 42:1191-1199.
16. Joshi S, Bharucha C, Jha S et al. Biosurfactant production using molasses and whey under thermophilic conditions. *Bioresource Technology* 2008; 99:195-199.
17. Rivera OMP, Moldes AB, Torrado AM et al. Lactic acid and biosurfactants production from hydrolyzed distilled grape marc. *Process Biochemistry* 2007; 42:1010-1020.
18. Moldes AB, Torrado AM, Barral MT et al. Evaluation of biosurfactant production from various agricultural residues by *Lactobacillus pentosus*. *Journal of Agriculture and Food Chemistry* 2007; 55:4481-4486.
19. Fiechter A. Biosurfactants: moving towards industrial application. *Trends in Biotechnology* 1992; 10:208-218.
20. Rodrigues LR, Teixeira JA, Oliveira R et al. Response surface optimization of the medium components for the production of biosurfactants by probiotic bacteria. *Process Biochemistry* 2006; 41:1-10.
21. Singh P, Cameotra S. Potential applications of microbial surfactants in biomedical sciences. *Trends in Biotechnology* 2004; 22:142-146.
22. Banat IM. Biosurfactants production and use in microbial enhanced oil recovery and pollution remediation: A review. *Bioresource Technology* 1995; 51:1-12.
23. Banat IM. Biosurfactants characterization and use in pollution removal: State of the art. A review. *Acta Biotechnologica* 1995; 15:25167.
24. Mulligan CN. Environmental application for biosurfactants. *Environmental Pollution* 2005; 133:183-198.
25. Banat IM, Makkar R, Cameotra S. Potential commercial applications of microbial surfactants. *Applied Microbiology and Biotechnology* 2000; 53:495-508.
26. Benincasa M, Abalos A, Oliveira I et al. Chemical structure, surface properties and biological activities of the biosurfactant produced by *Pseudomonas aeruginosa* LB1 from soapstock. *Antonie Van Leeuwenhoek* 2004; 85:1-8.
27. Flasz A, Rocha CA, Mosquera B et al. A comparative study of the toxicity of a synthetic surfactant and one produced by *Pseudomonas aeruginosa* ATCC 55925. *Medical Science Research* 1998; 6:181-185.
28. Rodrigues LR, Banat IM, Teixeira JA et al. Biosurfactants: Potential applications in medicine. *Journal of Antimicrobial Chemotherapy* 2006; 57:609-618.
29. Rodrigues LR, Banat IM, Teixeira JA et al. Strategies for the prevention of microbial biofilm formation on silicone rubber voice prostheses. *Journal of Biomedical Materials Research Part B Applied Biomaterials* 2007; 81B:358-370.
30. Maier RM. Biosurfactant: evolution and diversity in bacteria. *Advances in Applied Microbiology* 2003; 52:101-121.
31. Gerard J, Lloyd R, Barsby T et al. Massetolides A-H, antimycobacterial cyclic depsipeptides produced by two pseudomonads isolated from marine habitats. *Journal of Natural Products* 1997; 60:223-229.
32. Rodrigues LR, Banat IM, Van der Mei HC et al. Interference in adhesion of bacteria and yeasts isolated from explanted voice prostheses to silicone rubber by rhamnolipid biosurfactants. *Journal of Applied Microbiology* 2005; 100:470-480.
33. Lang S, Wullbrandt D. Rhamnose lipids—biosynthesis, microbial production and application potential. *Applied Microbiology and Biotechnology* 1999; 51:22-32.
34. Maier R, Soberon Chavez G. *Pseudomonas aeruginosa* rhamnolipids: biosynthesis and potential applications. *Applied Microbiology and Biotechnology* 2000; 54:625-633.

35. Das K, Mukherjee AK. Characterization of biochemical properties and biological activities of biosurfactants produced by *Pseudomonas aeruginosa* mucoid and nonmucoid strains isolated from hydrocarbon-contaminated soil samples. *Applied Microbiology and Biotechnology* 2005; 69:192-199.
36. Vollenbroich D, Pauli G, Ozel M et al. Antimycoplasmal properties and applications in cell culture of surfactin, a lipopeptide antibiotic from *Bacillus subtilis*. *Applied and Environmental Microbiology* 1997; 63:44-49.
37. Vollenbroich D, Ozel M, Vater J et al. Mechanism of inactivation of enveloped viruses by the biosurfactant surfactin from *Bacillus subtilis*. *Biologicals* 1997; 25:289-297.
38. Kameda Y, Ouchira S, Matsui Kkanatomo S et al. Antitumor activity of *Bacillus natto* V. Isolation and characterization of surfactin in the culture medium of *Bacillus natto* KMD 2311. *Chemistry and Pharmacology Bulletin* 1974; 22:938-944.
39. Bernheimer A, Avigad L. Nature and properties of a cytolytic agent produced by *Bacillus subtilis*. *Journal of Genetics and Microbiology* 1970; 61:361-69.
40. Sheppard JD, Jumarie C, Cooper DG et al. Ionic channels induced by surfactin in planar lipid bilayer membranes. *Biochimica et Biophysica Acta* 1991; 1064:13-23.
41. Itokawa H, Miyashita T, Morita H et al. Structural and conformational studies of [Ile7] and [Leu7] surfactins from *Bacillus subtilis*. *Chemistry and Pharmacology Bulletin* 1994; 42:604-607.
42. Wang CL, Ng TB, Yuan F et al. Induction of apoptosis in human leukemia K562 cells by cyclic lipopeptide from *Bacillus subtilis* natto T-2. *Peptides* 2007; 28:1344-1350.
43. Dehghan Noudel G, Housaindokht M, Bazzaz BSF. Isolation, characterization and investigation of surface and haemolytic activities of a lipopeptide biosurfactant produced by *Bacillus subtilis* ATCC 6633. *The Journal of Microbiology* 2005; 43:272-276.
44. Naruse N, Tenmyo O, Kobaru S et al. Pumilacidin, a complex of new antiviral antibiotics: production, isolation, chemical properties, structure and biological activity. *Journal of Antibiotics* 1990; 43:267-280.
45. Besson F, Peypoux F, Michel G et al. Characterization of iturin A in antibiotics from various strains of *Bacillus subtilis*. *Journal of Antibiotics* 1976; 29:1043-1049.
46. Thimon L, Peypoux F, Wallach J et al. Effect of lipopeptide antibiotic, iturin A, on morphology and membrane ultrastructure of yeast cells. *FEMS Microbiology Letters* 1995; 128:101-106.
47. Tanaka Y, Takashi T, Kazuhik U et al. Method of producing iturin A and antifungal agent for profound mycosis. *Biotechnology Advances* 1997; 15:234-235.
48. Mittenbuhler K, Loleit M, Baier W et al. Drug specific antibodies: T-cell epitope-lipopeptide conjugates are potent adjuvants for small antigens in vivo and in vitro. *International Journal of Immunopharmacology* 1997; 19:277-287.
49. Jenny K, Kappeli O, Fietcher A. Biosurfactants from *Bacillus licheniformis*: structural analysis and characterization. *Applied Microbiology and Biotechnology* 1991; 36:5-13.
50. Lin S, Carswell K, Sharma M. Continuous production of the lipopeptide biosurfactant of *Bacillus licheniformis* JF-2. *Applied Microbiology and Biotechnology* 1994; 41:281-285.
51. Yakimov M, Timmis K, Wray V et al. Characterization of a new lipopeptide surfactant produced by thermotolerant and halotolerant subsurface *Bacillus licheniformis* BAS50. *Applied and Environmental Microbiology* 1995; 61:1706-1713.
52. Grangemard I, Wallach J, Maget Dana R et al. Lichenysin: A more efficient cation chelator than surfactin. *Applied Biochemistry and Biotechnology* 2001; 90:199-210.
53. Kitamoto D, Yanagishita H, Shinbo T et al. Surface active properties and antimicrobial activities of mannosylerythritol lipids as biosurfactants produced by *Candida antarctica*. *Journal of Biotechnology* 1993; 29:91-96.
54. Isoda H, Kitamoto D, Shinmoto H et al. Microbial extracellular glycolipid induction of differentiation and inhibition of protein kinase C activity of human promyelocytic leukaemia cell line HL60. *Bioscience Biotechnology and Biochemistry* 1997; 61:609-614.
55. Isoda H, Shinmoto H, Matsumura M et al. The neurite-initiating effect of microbial extracellular glycolipids in PC12 cells. *Cytotechnology* 1999; 31:163-170.
56. Shibahara M, Zhao X, Wakamatsu Y et al. Mannosylerythritol lipid increases levels of galactoceramide in and neurite outgrowth from PC12 pheochromocytoma cells. *Cytotechnology* 2000; 33:247-251.
57. Zhao X, Geltinger C, Kishikawa S et al. Treatment of mouse melanoma cells with phorbol 12-myristate 13-acetate counteracts mannosylerythritol lipid-induced growth arrest and apoptosis. *Cytotechnology* 2000; 33:123-130.
58. Zhao X, Wakamatsu Y, Shibahara M et al. Mannosylerythritol lipid is a potent inducer of apoptosis and differentiation of mouse melanoma cells in culture. *Cancer Research* 1999; 59:482-486.
59. Wakamatsu Y, Zhao X, Jin C et al. Mannosylerythritol lipid induces characteristics of neuronal differentiation in PC12 cells through an ERK-related signal cascade. *European Journal of Biochemistry* 2001; 268:374-383.

60. Ueno Y, Hirashima N, Inoh Y et al. Characterization of biosurfactant-containing liposomes and their efficiency for gene transfection. *Biological and Pharmaceutical Bulletin* 2007; 30:169-172.
61. Ueno Y, Inoh Y, Furuno T et al. NBD-conjugated biosurfactant (MEL-A) shows a new pathway for transfection. *Journal of Controlled Release* 2007; 123:247-253.
62. Shah V, Badia D, Ratsep P. Sophorolipids having enhanced antibacterial activity. *Antimicrobial Agents and Chemotherapy* 2007; 51:397-400.
63. Maitani Y, Yano S, Hattori Y et al. Liposome vector containing biosurfactant-complexed DNA as herpes simplex virus thymidine kinase gene delivery system. *Journal of Liposome Research* 2006; 16:359-372.
64. Konishi M, Imura T, Fukuoka T et al. A yeast glycolipid biosurfactant, mannosylerythritol lipid, shows high binding affinity towards lectins on a self-assembled monolayer system. *Biotechnology Letters* 2007; 29:473-480.
65. Ito S, Imura T, Fukuoka T et al. Kinetic studies on the interactions between glycolipid biosurfactant assembled monolayers and various classes of immunoglobulins using surface plasmon resonance. *Colloids and Surfaces B: Biointerfaces* 2007; 58:165-171.
66. Igarashi S, Hattori Y, Maitani Y. Biosurfactant MEL-A enhances cellular association and gene transfection by cationic liposome. *Journal of Controlled Release* 2006; 112:362-368.
67. Uchida Y, Misava S, Nakahara T et al. Factor affecting the production of succinotrehalose lipids by *rodococcus erythropolis* SD-74 grown on n-alkanes. *Agriculture and Biological Chemistry* 1989; 53:765-769.
68. Uchida Y, Tsuchiya R, Chino M et al. Extracellular accumulation of mono and di succinyl trehalose lipids by a strain of *rodococcus erythropolis* grown on n-alkanes. *Agriculture and Biological Chemistry* 1989; 53:757-763.
69. Busscher HJ, Neu T, Van der Mei HC. Biosurfactant production by thermophilic dairy streptococci. *Applied Microbiology and Biotechnology* 1994; 41:4-7.
70. Rodrigues LR, Van der Mei HC, Teixeira J et al. The influence of biosurfactants from probiotic bacteria on the formation of voice prosthetic biofilms. *Applied and Environmental Microbiology* 2004; 70:4408-4410.
71. Rodrigues LR, Van der Mei HC, Banat IM et al. Inhibition of microbial adhesion to silicone rubber treated with biosurfactant from *streptococcus thermophilus* A. *FEMS Immunology and Medical Microbiology* 2004; 6:107-125.
72. Busscher HJ, Van Hoogmoed CG, Geertsema Doornbusch GI et al. *Streptococcus thermophilus* and its biosurfactants inhibit adhesion by *candida* spp on silicone rubber. *Applied and Environmental Microbiology* 1997; 63:3810-3817.
73. Busscher HJ, Van de Belt-Gritter B, Westerhof M et al. Microbial interference in the colonization of silicone rubber implant surfaces in the oropharynx: *Streptococcus thermophilus* against a mixed fungal/bacterial biofilm. In: *Microbial Ecology and Infectious Disease*. ed. Rosenberg, E. Washington D.C.: American Society for Microbiology 1999; 66-74.
74. Pratt Terpstra IH, Weerkamp AH, Busscher HJ. Microbial factors in a thermodynamic approach of oral streptococcal adhesion to solid substrata. *Journal of Colloid Interface Science* 1989; 129:568-574.
75. Van Hoogmoed CG, Van der Kuyl Booij M, Van der Mei HC et al. Inhibition of streptococcus mutants NS adhesion to glass with and without a salivary conditioning film by biosurfactant-releasing streptococcus mitis strain. *Applied and Environmental Microbiology* 2000; 66:659-663.
76. Velraeds M, Van der Mei HC, Reid G et al. Inhibition of initial adhesion of uropathogenic enterococcus faecalis to solid substrata by an adsorbed biosurfactant layer from *Lactobacillus acidophilus*. *Urology* 1997; 49:790-794.
77. Reid G, Zalai C, Gardiner G. Urogenital *Lactobacilli* probiotics, reliability and regulatory issues. *Journal of Dairy Science* 1984; 84:164-169.
78. Reid G, Heinemann C, Velraeds M et al. Biosurfactants produced by *lactobacillus*. *Methods Enzymology* 1999; 310:426-433.
79. Velraeds M, Van der Mei HC, Reid G et al. Physicochemical and biochemical characterization of biosurfactants released by *Lactobacillus* strains. *Colloids Surface B Biointerfaces* 1996; 8:51-61.
80. Velraeds M, Van der Mei HC, Reid G et al. Inhibition of initial adhesion of uropathogenic enterococcus faecalis by biosurfactants from *lactobacillus* isolates. *Applied and Environmental Microbiology* 1996; 62:1958-1963.
81. Gorek P, Bednarski W, Lewandowska M. Characterization of adhesive properties of *lactobacillus* strains synthesising biosurfactants. *Polish Journal of Natural Sciences* 2007; 22:333-342.
82. Rodrigues LR, Van der Mei HC, Teixeira J et al. Biosurfactant from *lactococcus lactis* 53 inhibit microbial adhesion on silicone rubber. *Applied Microbiology and Biotechnology* 2004; 66:306-311.
83. Kikuchi T, Hasumi K. Enhancement of reciprocal activation of prourokinase plasminogen by the bacterial lipopeptide surfactins and iturins. *Journal of Antibiotics* 2003; 56:34-37.

84. Van Bogaert INA, Saerens K, De Muynck C et al. Microbial production and application of sophorolipids. *Applied Microbiology and Biotechnology* 2007; 76:23-34.
85. Sudo T, Zhao X, Wakamatsu Y et al. Induction of the differentiation of human HL-60 promyelocytic leukemia cell line by succinoyl trehalose lipids. *Cytotechnology* 2000; 33:259-264.
86. Im J, Nakane T, Yanagishita H et al. Mannosylerythritol lipid, a yeast extracellular glycolip, shows high binding affinity towards human immunoglobulin G. *BMC Biotechnology* 2001; 1-5.
87. Im JH, Yanagishita H, Ikegami T et al. Mannosylerythritol lipids, yeast glycolipid biosurfactants, are potential affinity ligand materials for human immunoglobulin G. *Journal of Biomedical Materials Research* 2003; 65:379-385.
88. Inoh Y, Kitamoto D, Hirashima N et al. Biosurfactants of MEL-A increase gene transfection mediated by cationic liposomes. *Biochemistry and Biophysics Research Communications* 2001; 289:57-61.
89. Inoh Y, Kitamoto D, Hirashima N et al. Biosurfactant MEL-A dramatically increases gene transfection via membrane fusion. *Journal of Controlled Release* 2004; 94:423-431.
90. Kitamoto D, Isoda H, Nakahara T. Functions and potential applications of glycolipid biosurfactants—from energy-saving materials to gene delivery carriers. *Journal of Bioscience and Bioengineering* 2002; 94:187-201.
91. Wright JR. Pulmonary surfactant: a front line of lung host defense. *Journal of Clinical Investigation* 2003; 111:1453-1455.
92. Sano H, Sohma H, Muta T et al. Pulmonary surfactant protein A modulates the cellular response to smooth and rough lipopolysaccharides by interaction with CD14. *Journal of Immunology* 1999; 163:387-395.
93. Sen R, Swaminathan T. Characterization of concentration and purification parameters and operating conditions for the small-scale recovery of surfactin. *Process Biochemistry* 2005; 40:2953-2958.
94. Carrillo C, Teruel J, Aranda F et al. Molecular mechanism of membrane permeabilization by the peptide antibiotic surfactin. *Biochimica and Biophysica Acta* 2003; 1611:91-97.
95. Kim K, Jung SY, Lee DK et al. Suppression of inflammatory responses by surfactin, a selective inhibitor of platelet cytosolic phospholipase A2. *Biochemical Pharmacology* 1998; 55:975-985.
96. Kikuchi T, Hasumi K. Enhancement of plasminogen activation by surfactin C: augmentation of fibrinolysis in vitro and in vivo. *Biochimica and Biophysica Acta* 2002; 1596:234-245.
97. Moyne AL, Shelby R, Cleveland TE et al. Bacillomycin D: an iturin with antifungal activity against *aspergillus flavus*. *Journal of Applied Microbiology* 2001; 90:622-629.
98. Kosaric N. Biosurfactants. In: *Biotechnology*. ed. Rehm HJ, Reed G, Puhler A et al. P. Weinheim: VCH 1996; 659-717.
99. Nielsen T, Christophersen C, Anthoni U et al. Viscosinamide, a new cyclic depsipeptide with surfactant and antifungal properties produced by *pseudomonas fluorescens* DR54. *Journal of Applied Microbiology* 1999; 86:80-90.
100. Neu T, Hartner T, Poralla K. Surface active properties of viscosin: a peptidolipid antibiotic. *Applied Microbiology and Biotechnology* 1990; 32:518-20.
101. Bidet DJ, Aly R, Shinefield HR. Inhibition of microbial adherence by sphinganine. *Canadian Journal of Microbiology* 1992; 38:983-985.
102. Van Delden C, Iglewski B. Cell-to-cell signaling and *pseudomonas aeruginosa* infections. *Emerging Infectious Diseases* 1998; 4:551-560.
103. Ishigami Y, Suzuki S. Development of biochemicals—functionalization of biosurfactants and natural dyes. *Progress on Organic Coatings* 1997; 31:51-61.
104. Ramisse F, Delden C, Gidenne S et al. Decreased virulence of a strain of *pseudomonas aeruginosa* O12 overexpressing a chromosomal type 1 b-lactamase could be due to reduced expression of cell-to-cell signaling dependent virulence factors. *FEMS Immunology and Medical Microbiology* 2000; 28:241-245.
105. Sotirova A, Spasova D, Vasileva Tonkova E et al. Effects of rhamnolipid-biosurfactant on cell surface of *pseudomonas aeruginosa*. *Microbiological Research* 2007; In press.
106. Mireles JR, Toguchi A, Harshey RM. *Salmonella enterica* serovar typhimurium swarming mutants with altered biofilm formation abilities: surfactin inhibits biofilm formation. *Journal of Bacteriology* 2001; 183:5848-5854.
107. Boris S, Barbés C. Role played by lactobacilli in controlling the population of vaginal pathogens. *Microbes Infection* 2000; 2:543-546.
108. Velraeds M, Van de Belt Gritter B, Van der Mei HC et al. Interference in initial adhesion of uropathogenic bacteria and yeasts to silicone rubber by a *Lactobacillus acidophilus* biosurfactant. *Journal of Medical Microbiology* 1998; 47:1081-1085.
109. Reid G. In vitro testing of *Lactobacillus acidophilus* NCFM as a possible probiotic for the urogenital tract. *International Dairy Journal* 2000; 10:415-419.

110. Heinemann C, Van Hylckama V, Janssen D et al. Purification and characterization of a surface-binding protein from *Lactobacillus fermentum* RC-14 that inhibits adhesion of *Enterococcus faecalis* 1131. *FEMS Microbiology Letters* 2000; 190:177-180.
111. Cameotra S, Makkar R. Recent applications of biosurfactants as biological and immunological molecules. *Current Opinion Microbiology* 2004; 7:262-266.
112. Reid G, Bruce A, Smeianov V. The role of *Lactobacilli* in preventing urogenital and intestinal infections. *International Dairy Journal* 1998; 8:555-562.
113. Reid G, Bruce A, Fraser N et al. Oral probiotics can resolve urogenital infections. *FEMS Immunology and Medical Microbiology* 2001; 30:49-52.
114. Gan B, Kim J, Reid G et al. *Lactobacillus fermentum* RC-14 inhibits *staphylococcus aureus* infection of surgical implants in rats. *Journal of Infectious Diseases* 2002; 185:1369-1372.
115. Mack DR, Michail S, Wei S et al. Probiotics inhibit enteropathogenic *E. coli* adherence in vitro by inducing intestinal mucin gene expression. *American Journal of Physiology* 1999; 276:941-950.
116. Millsap K, Reid G, Van der Mei HC et al. Adhesion of *Lactobacillus* species in urine and phosphate buffer to silicone rubber and glass under flow. *Biomaterials* 1996; 18:87-91.